Journal article
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
RA Herbertson, NC Tebbutt, FT Lee, DJ MacFarlane, B Chappell, N Micallef, ST Lee, T Saunder, W Hopkins, FE Smyth, DK Wyld, J Bellen, DS Sonnichsen, MW Brechbiel, C Murone, AM Scott
Clinical Cancer Research | Published : 2009
Abstract
Purpose: This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Ley) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Ley antigen. Experimental Design: The primary objectiveswere to determine biodistribution and pharmacokinetics of CMD-193. Secondary objectives included response rates and change in tumor metabolism. Patients with progressive, measurable, and Ley positive malignancies were eligible for enrollment in one of two dose cohorts, 1.0 and 2.6 mg/m2. The first cycle was trace labeled with 111In for biodistribution assessment using υ camera imaging. Subsequent cycleswere admi..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Wyeth Pharmaceuticals, Inc. provided financial support and pharmaceutical investigation compound CMD-193 for the study. The Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research supports Martin W. Brechbiel.